BG63943B1 - (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат - Google Patents
(-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат Download PDFInfo
- Publication number
- BG63943B1 BG63943B1 BG102474A BG10247498A BG63943B1 BG 63943 B1 BG63943 B1 BG 63943B1 BG 102474 A BG102474 A BG 102474A BG 10247498 A BG10247498 A BG 10247498A BG 63943 B1 BG63943 B1 BG 63943B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- phenyl
- preparation
- cis
- composition
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US612595P | 1995-11-02 | 1995-11-02 | |
PCT/IB1996/001049 WO1997016434A1 (en) | 1995-11-02 | 1996-10-04 | (-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate |
Publications (2)
Publication Number | Publication Date |
---|---|
BG102474A BG102474A (en) | 1999-06-30 |
BG63943B1 true BG63943B1 (bg) | 2003-07-31 |
Family
ID=21719433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102474A BG63943B1 (bg) | 1995-11-02 | 1998-05-21 | (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат |
Country Status (43)
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
GB9703109D0 (en) * | 1997-02-14 | 1997-04-02 | Smith & Nephew | Compositions |
ZA993975B (en) * | 1998-06-16 | 2000-12-15 | Pfizer Prod Inc | Combination therapy for musculoskeletal frailty. |
DK0966968T3 (da) | 1998-06-16 | 2004-08-30 | Pfizer Prod Inc | Terapeutiske kombinationer, der omfatter en selektiv östrogenreceptormodulator og prostaglandin E2 |
OA11569A (en) * | 1998-06-16 | 2004-07-01 | Pfizer Prod Inc | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. |
YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
IL152082A0 (en) * | 2000-04-07 | 2003-05-29 | Pfizer Prod Inc | Estrogen agonist/antagonist metabolites |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
EP1156120B1 (en) | 2000-05-08 | 2006-11-22 | Pfizer Products Inc. | Enzymatic resolution of selective estrogen receptor modulators |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
TWI303990B (en) | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
KR100568380B1 (ko) | 2001-05-01 | 2006-04-05 | 화이자 프로덕츠 인코포레이티드 | 저 투약량 약학 조성물의 제조 방법 |
WO2003011282A1 (en) | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
RU2317104C2 (ru) * | 2001-09-24 | 2008-02-20 | Импиэриэл Инноувейшнс Лимитид | Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения |
HUP0500025A3 (en) * | 2002-03-28 | 2005-10-28 | Pfizer Prod Inc | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
EP1765461A1 (en) * | 2004-06-21 | 2007-03-28 | Pharmacia & Upjohn Company LLC | Pyk2 inhibitors for stimulation of osteoblast function |
BRPI0512245A (pt) * | 2004-06-30 | 2008-02-19 | Lilly Co Eli | composto, composição farmacêutica, e, uso do composto |
WO2006136944A1 (en) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride |
CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
WO2010125578A2 (en) | 2009-04-29 | 2010-11-04 | Glenmark Generics Limited | A process for the preparation of lasofoxifene tartrate |
KR101149529B1 (ko) | 2009-09-11 | 2012-05-25 | 한국화학연구원 | 인덴온 유도체 및 이를 포함하는 약학적 조성물 |
CN103113323B (zh) * | 2013-02-05 | 2015-11-11 | 南京华威医药科技开发有限公司 | 酒石酸拉索昔芬中间体的制备方法 |
CN112353796A (zh) | 2016-10-11 | 2021-02-12 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
CN112261937B (zh) | 2018-04-10 | 2023-11-14 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
KR20220115062A (ko) | 2021-02-09 | 2022-08-17 | (주)오스티오뉴로젠 | 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3234090A (en) * | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
-
1996
- 1996-04-10 UA UA98042214A patent/UA51676C2/uk unknown
- 1996-09-30 TW TW091125091A patent/TW581766B/zh not_active IP Right Cessation
- 1996-09-30 TW TW085111903A patent/TW518327B/zh not_active IP Right Cessation
- 1996-10-04 BR BR9611436A patent/BR9611436A/pt not_active Application Discontinuation
- 1996-10-04 HU HU9900087A patent/HU227521B1/hu unknown
- 1996-10-04 DE DE69629837T patent/DE69629837T2/de not_active Expired - Lifetime
- 1996-10-04 CA CA002236673A patent/CA2236673C/en not_active Expired - Lifetime
- 1996-10-04 ES ES96931206T patent/ES2203713T3/es not_active Expired - Lifetime
- 1996-10-04 IL IL12402796A patent/IL124027A/en not_active IP Right Cessation
- 1996-10-04 WO PCT/IB1996/001049 patent/WO1997016434A1/en active IP Right Grant
- 1996-10-04 US US09/065,094 patent/US5948809A/en not_active Expired - Lifetime
- 1996-10-04 TR TR1998/00783T patent/TR199800783T2/xx unknown
- 1996-10-04 JP JP09517180A patent/JP3088020B2/ja not_active Expired - Lifetime
- 1996-10-04 EP EP96931206A patent/EP0876359B1/en not_active Expired - Lifetime
- 1996-10-04 RU RU98110128/04A patent/RU2162465C2/ru active
- 1996-10-04 CZ CZ19981320A patent/CZ287341B6/cs not_active IP Right Cessation
- 1996-10-04 SK SK542-98A patent/SK282172B6/sk not_active IP Right Cessation
- 1996-10-04 CN CN96198048A patent/CN1067065C/zh not_active Expired - Lifetime
- 1996-10-04 RO RO98-00926A patent/RO119829B1/ro unknown
- 1996-10-04 DK DK96931206T patent/DK0876359T3/da active
- 1996-10-04 PL PL96326498A patent/PL188633B1/pl unknown
- 1996-10-04 KR KR1019980703251A patent/KR19990067280A/ko not_active Application Discontinuation
- 1996-10-04 PT PT96931206T patent/PT876359E/pt unknown
- 1996-10-04 NZ NZ318498A patent/NZ318498A/xx not_active IP Right Cessation
- 1996-10-04 AU AU69984/96A patent/AU708841B2/en not_active Expired
- 1996-10-04 AT AT96931206T patent/ATE248827T1/de active
- 1996-10-04 SI SI9630635T patent/SI0876359T1/xx unknown
- 1996-10-11 GT GT199600085A patent/GT199600085A/es unknown
- 1996-10-23 AR ARP960104862A patent/AR004078A1/es active IP Right Grant
- 1996-10-29 HR HR960503A patent/HRP960503B1/xx not_active IP Right Cessation
- 1996-10-30 DZ DZ960158A patent/DZ2114A1/fr active
- 1996-10-30 MA MA24381A patent/MA23998A1/fr unknown
- 1996-10-30 TN TNTNSN96134A patent/TNSN96134A1/fr unknown
- 1996-10-30 PE PE1996000753A patent/PE17698A1/es not_active Application Discontinuation
- 1996-10-30 EG EG95996A patent/EG21095A/xx active
- 1996-10-31 AP APAP/P/1996/000880A patent/AP713A/en active
- 1996-11-01 CO CO96057925A patent/CO4770967A1/es unknown
- 1996-11-01 YU YU57896A patent/YU49123B/sh unknown
- 1996-11-01 ZA ZA9609212A patent/ZA969212B/xx unknown
- 1996-11-04 UY UY24362A patent/UY24362A1/es unknown
-
1998
- 1998-04-16 IS IS4718A patent/IS1855B/is unknown
- 1998-04-29 OA OA9800046A patent/OA11009A/en unknown
- 1998-04-30 NO NO19981962A patent/NO310358B1/no not_active IP Right Cessation
- 1998-05-21 BG BG102474A patent/BG63943B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG63943B1 (bg) | (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат | |
US6153622A (en) | Estrogen agonists/antagonists | |
US5589482A (en) | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia | |
JP2000080038A (ja) | エストロゲンアゴニスト及びアンタゴニスト | |
MXPA98003544A (en) | D-tartrate (-) - cis-6 (s) -fenil-5 (r) - [4- (2-pyrrolidin-1-iletoxy) phenyl] -5,6,7,8-tetrahydronatalen-2 | |
SA96170352B1 (ar) | (-)cis-6(S)-phenyl-5®[4-(2-pyrrolidin-1-y1ethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol-D-tartrate |